Scolaris Content Display Scolaris Content Display

Zinc supplementation for the prevention of type 2 diabetes mellitus

This is not the most recent version

References

Additional references

ADA 1998

American Diabetes Association. [Screening for Type 2 Diabetes]. Diabetes Care 1998;22(supp1):S20‐3.

ADA 1999

American Diabetes Association. [Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus]. Diabetes Care 1999;22(1):S5‐S19.

Alderson 2004

Alderson P, Green S, Huggins JPT, editors. [Cochrane Reviewers' Handbook 4.2.2. Assessment of study quality. Section 4]. The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration. Chichester: John Wiley & Ltd.; 2004, Issue 1.

Barbara B 2000

Kahn BB, Flier JS. [Obesity and insulin resistance]. The journal of clinical Investigation 2000;106(4):473‐81.

Bonora 1998

Bonora E, Kiechi E, Willeit J, Oberhollenzer F, Egger G, Targher G, et al. [Prevalence of insulin resistance in metabolic disorders]. Diabetes 1998;47:1643‐9.

Bonora 2000

Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. [Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity]. Diabetes Care 2000;23(1):57‐63.

Cohen 1960

Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37‐46.

DeFronzo 1979

DeFronzo RA, Tobin JD, Andres R. [Glucose Clamp technique: a method for quantifying insulin secretion and resistance]. The American Journal of Physiology 1979; 237: E214‐E223;237:E214‐E223.

Handbook 2004

Anderson P, Green S, Higgins JPT. Identifying and measuring hetereogeneity. The Cochrane Library [database on CDROM]. The Cochrane Collaboration. Chichester: John Wiley & Sons. Ltd.; 2005, Issue 1.

Higgins 2003

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. [Measuring inconsistency in meta‐analysis]. BMJ 2003;327:555‐7.

Howard 1996

Howard G, O´Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, et al. [Insulin sensitivity and atherosclerosis: the insulin resistance atherosclerosis study (IRAS) Investigators]. Circulation 1996;93:1809‐17.

Jadad 1996

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds JM, Gavaghan DJ, et al. [Assessing the Quality of Reports of Randomised Clinical Trials: Is Blinding necessary?]. Controlled Clinical Trials 1996;17:1‐12.

Karelis 2004

Karelis AD, Henry JF, Malita F, ST‐Pierre DH, Vigneault I, Poehlman ET, Rabasa‐Lhoret R. [Comparison of insulin sensitivity values using the hyperinsulinemic euglycemic clamp: 2 vs 3 hours]. Diabetes & Metabolism 2004;30:413‐4.

Marchesini 1998

Marchesini G, Bugianesi E, Ronchi M, Flamia R, Thomaseth K, Pacini G. [Zinc supplementation improves glucose disposal in patients with cirrhosis]. Metabolism: Clinical and Experimental 1998;47(7):792‐8.

Marreiro 2004

Marreiro DN, Geloneze B, Tambascia MA, Lerário AC, Halpern A, Cozzolino SMF. Participation of zinc in insulin resistance [Participaçäo do zinco na resistência à insulina]. Arquivos brasileiros de endocrinologia e metabologia 2004;48(2):234‐9.

Matthews 1985

Matthews DR, Hoster JP, Rudenski BA, Naylor DF, Treacher RC. [Homeostasis model assessment: insulin resistance and B‐cell function from fasting plasma glucose and insulin concentrations in man]. Diabetologia 1985;28:412‐9.

Moro 2003

Moro E, Gallina P, Pais M, Cazzolato G, Alessandrini P, Bittolo‐Bon G. [Hypertriglyceridemia is associated with increased insulin resistance in subjests assessed with the 1999 World Health Organization criteria for the classification of diabetes]. Metabolism: Clinical and Experimental 2003;52(5):616‐9.

Rossetti 1990

Rossetti L, Giaccari A, Klein‐Robbenhaar E, Vogel LR. [Insulinomimetic properties of trace elements and characterization of their in vivo mode of action]. Diabetes 1990;39:1243‐50.

Schulz 1995

Schulz KF, Chalmers I, Hayes RJ, Altman DJ. [Empirical Evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials]. JAMA 1995;273(5):408‐12.

Tracey L 2003

Tracey L, Mclaughlin MD, Gerald M, Reaven MD. [Beyond type 2 Diabetes: The need for a clinically useful way to identify insulin resistance]. The American Journal of Medicine 2003;114:501‐2.

WHO 1997

World Health Organization. The World Health Report. Geneva: WHO, 1997.

WHO 2000

World Health Organization. [Prevalence of Diabetes WorldWide 2000,2030]. disponível em: http// www.who.int/diabetes/facts/world_figures/ (assessed 21 June 2005).
Table 1. Table 01 Search Strategy for identification of studies

Database

Search strategy

Unless otherwise stated, search terms were free text terms; exp = exploded MeSH: Medical subject heading (Medline medical index term); the dollar sign ($) stands for any character(s); the question mark (?) = to substitute for one or no characters; tw = text word; pt = publication type; sh = MeSH: Medical subject heading (Medline medical index term); adj = adjacency.

Medline (OVID)

(1) exp ZINC/
(2) zinc.tw.
(3) 1 or 2
(4) exp diabetes mellitus/
(5) diabet$.tw.
(6) IDDM.tw.
(7) NIDDM.tw.
(8) MODY.tw.
(9) (late onset adj diabet$).tw.
(10) (maturity onset adj diabet$).tw.
(11) (juvenil adj diabet$).tw.
(12) exp Syndrome X/
(13) (syndrome X and diabet$).tw.
(14) hyperinsulin$.tw.
(15) insulin sensitiv$.tw.
(16) insulin$ secret$ dysfunc$.tw.
(17) impaired glucose toleran$.tw.
(18) glucose intoleran$.tw.
(19) exp Glucose Intolerance/
(20) insulin$ resist$.tw.
(21) (non insulin$ depend$ or noninsulin$ depend$ or non insulin?depend$ or noninsulin?depend$).tw.
(22) metabolic$ syndrom$.tw.
(23) (pluri metabolic$ syndrom$ or plurimetabolic$ syndrom$).tw.
(24) ((typ$ 1 or typ$ 2) and diabet$).tw.
(25) ((typ$ I or typ$ II) and diabet$).tw.
(26) exp Insulin Resistance/
(27) (insulin$ depend$ or insulin?depend$).tw.
(28) or/4‐27
(29) limit 28 to human
(30) randomized controlled trial.pt.
(31) controlled clinical trial.pt.
(32) randomized controlled trials.sh.
(33) random allocation.sh.
(34) double‐blind method.sh.
(35) single‐blind method.sh.
(36) or/30‐35
(37) limit 36 to animal
(38) limit 36 to human
(39) 37 not 38
(40) 36 not 39
(41) clinical trial.pt.
(42) exp clinical trials/
(43) (clinic$ adj25 trial$).tw.
(44) ((singl$ or doubl$ or trebl$ or tripl$) adj (mask$ or blind$)).tw.
(45) placebos.sh.
(46) placebo$.tw.
(47) random$.tw.
(48) research design.sh.
(49) (latin adj square).tw.
(50) or/41‐49
(51) limit 50 to animal
(52) limit 50 to human
(53) 51 not 52
(54) 50 not 53
(55) comparative study.sh.
(56) exp evaluation studies/
(57) follow‐up studies.sh.
(58) prospective studies.sh.
(59) (control$ or prospectiv$ or volunteer$).tw.
(60) cross‐over studies.sh.
(61) or/55‐ 60
(62) limit 61 to animal
(63) limit 61 to human
(64) 62 not 63
(65) 61 not 64
(66) 40 or 54 or 65
(67) 3 and 29 and 66

Lilacs

#1 = Zinc OR (Serum Zinc Level$) #2 = (Adult‐Onset Diabetes Mellitus) OR (Adult Onset Diabetes Mellitus) OR (Ketosis‐Resistant Diabetes Mellitus) OR (Ketosis Resistant Diabetes Mellitus) OR (Maturity‐Onset Diabetes Mellitus) OR (Maturity Onset Diabetes Mellitus) OR (Non Insulin Dependent Diabetes Mellitus)
OR (Non‐Insulin‐Dependent Diabetes Mellitus) OR (Noninsulin Dependent Diabetes Mellitus) OR (Slow‐Onset Diabetes Mellitus) OR (Slow Onset Diabetes Mellitus) OR (Stable Diabetes Mellitus) OR (Type II Diabetes Mellitus) OR MODY OR NIDDM OR (Type 2 Diabetes Mellitus) OR (insulin resistance) OR Hyperinsulinemia OR (Compensatory Hyperinsulinemia) OR (Endogenous Hyperinsulinism) OR (Exogenous Hyperinsulinism) OR (Glucose Metaboli$ Disorder$) OR (Glucose intolerance$) OR hyperglycemia$ #3 = (Pt randomized controlled trial) OR (Pt controlled clinical trial) OR (Mh randomized controlled trials) OR (Mh random allocation) OR (Mh double blind method) OR (Mh single blind method) AND NOT (Ct animal) AND NOT (Ct human and Ct animal) OR (Pt clinical trial) OR (Ex E05.318.760.535$) OR (Tw clin$) AND (Tw trial$) OR (Tw ensa$) OR (Tw estud$) OR (Tw experim$) OR (Tw investiga$) OR (Tw singl$) OR (Tw simple$) OR (Tw doubl$) OR (Tw doble$) OR (Tw duplo$) OR (Tw trebl$) OR (Tw trip$) AND (Tw blind$) OR (Tw cego$) OR (Tw ciego$) OR (Tw mask$) OR (Tw mascar$) OR (Mh placebos) OR (Tw placebo$) OR (Tw random$) OR (Tw randon$) OR (Tw casual$) OR (Tw acaso$) OR (Tw azar) OR (Tw aleator$) OR (Mh research design) AND NOT (Ct animal) AND NOT (Ct human and Ct animal) OR (Ct comparative study) OR (Ex E05.337$) OR (Mh follow‐up studies) OR (Mh prospective studies) OR (Tw control$) OR (Tw prospectiv$) OR (Tw volunt$) OR (Tw volunteer$) AND NOT ((Ct animal) AND NOT (Ct human and Ct animal))

Figures and Tables -
Table 1. Table 01 Search Strategy for identification of studies